FindTrial
Sign In

Rivaroxaban-Placebo

DRUG2 trials

Sponsors

Bayer

Conditions

Peripheral Artery DiseaseStroke

Phase 3

Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)
TerminatedNCT02313909
BayerStroke
Start: 2014-12-23End: 2018-02-15Updated: 2019-01-09
Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities
CompletedNCT02504216
BayerPeripheral Artery Disease
Start: 2015-08-18End: 2020-01-09Updated: 2020-12-08

Related Papers

Low-Dose Rivaroxaban Plus Aspirin in Patients With PAD Undergoing Lower Extremity Revascularization With and Without History of Prior Limb Revascularization: Insight From the VOYAGER-PAD Trial
Circulation Cardiovascular Interventions2026-02-27
Rivaroxaban in Peripheral Artery Disease After Revascularization: Worst Events and Net Outcomes in VOYAGER PAD.
2025-10-231 citations
Improving analysis of cognitive outcomes in cardiovascular trials using different statistical approaches.
2024-10-02
Methods, design, and initial results of an angiographic core lab from VOYAGER-PAD
Vascular Medicine2024-03-17
Sex‐Based Differences in Outcomes Following Peripheral Artery Revascularization: Insights From VOYAGER PAD
Journal of the American Heart Association2022-06-1413 citations
Improvement in walking impairment following surgical and endovascular revascularization: Insights from VOYAGER PAD
Vascular Medicine2022-04-257 citations
Rivaroxaban versus aspirin for prevention of covert brain infarcts in patients with embolic stroke of undetermined source: NAVIGATE ESUS MRI substudy.
2021-11-189 citations
Safety and Effectiveness of Paclitaxel Drug-Coated Devices in Peripheral Artery Revascularization: Insights From VOYAGER PAD.
2021-11-0121 citations
Left Ventricular Dysfunction Among Patients With Embolic Stroke of Undetermined Source and the Effect of Rivaroxaban vs Aspirin
JAMA Neurology2021-10-2540 citations
Reduction in Acute Limb Ischemia With Rivaroxaban Versus Placebo in Peripheral Artery Disease After Lower Extremity Revascularization: Insights From VOYAGER PAD
Circulation2021-10-1239 citations
Frequency and Patterns of Brain Infarction in Patients With Embolic Stroke of Undetermined Source: NAVIGATE ESUS Trial
Stroke2021-09-2015 citations
Effect of Rivaroxaban and Aspirin in Patients With Peripheral Artery Disease Undergoing Surgical Revascularization: Insights From the VOYAGER PAD Trial
Circulation2021-08-1247 citations
Total Ischemic Event Reduction With Rivaroxaban After Peripheral Arterial Revascularization in the VOYAGER PAD Trial
Journal of the American College of Cardiology2021-05-1652 citations
Abstract 13474: Rivaroxaban Reduces Major Cardiovascular and Limb Events in Patients With the High-risk Triad of Chronic Kidney Disease, Peripheral Artery Disease and Recent Lower Extremity Revascularization: Insights From VOYAGER PAD
Circulation2020-11-171 citations
Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization
Circulation2020-11-03102 citations
Microbleeds and the Effect of Anticoagulation in Patients With Embolic Stroke of Undetermined Source
JAMA Neurology2020-10-1941 citations
High-Sensitivity Cardiac Troponin T for Risk Stratification in Patients With Embolic Stroke of Undetermined Source
Stroke2020-07-0924 citations
Characteristics of Recurrent Ischemic Stroke After Embolic Stroke of Undetermined Source
JAMA Neurology2020-07-0659 citations
Frequency and Predictors of Major Bleeding in Patients With Embolic Strokes of Undetermined Source
Stroke2020-06-109 citations
Potential Embolic Sources and Outcomes in Embolic Stroke of Undetermined Source in the NAVIGATE-ESUS Trial
Stroke2020-04-1674 citations

8 more papers not shown